Comment on: Comparative dissolution profiles of two anti-emetic delayed-release dosage forms of doxylamine and pyridoxine: Xonvea® tablets vs. Cariban® capsules

被引：0

|

作者：

Urso, K. ^{[1
]}

Saz-Leal, P. ^{[1
]}

Dominguez, L. Zamorano ^{[1
]}

Mangrella, M. ^{[2
]}

机构：

[1] ITF Res Pharm SLU, Alcobendas, Spain

[2] Italfarmaco SpA, Milan, Italy

来源：

EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES | 2022年 / 26卷 / 22期

关键词：

STABILITY;

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

收藏

页码：8206 / 8208

页数：3

相关论文

共 3 条

[1] Comparative dissolution profiles of two anti-emetic delayed release dosage forms of doxylamine and pyridoxine: Xonvea® tablets vs. Cariban® capsules
Alcocer, C.
Iraola, M.
Rom, E.
Hoarau, D.
Gergic, E.
Perez de la Cruz, M. A.
Regidor, P-A
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2022, 26 (12) : 4420 - 4430
[2] Reply Letter - to Urso et al "Comment on: Comparative dissolution profiles of two anti-emetic delayed release dosage forms of doxylamine and pyridoxine: Xonvea® tablets vs. Cariban® capsules"
Alcocer, C.
Rom, E.
Regidor, P. A.
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2022, 26 (23) : 8635 - 8636
[3] Comparative absorption profiles of divalproex sodium delayed-release vs. extended-release tablets-clinical implications
Dutta, S
Reed, RC
O Dea, R
NEUROLOGY, 2005, 64 (06) : A189 - A190